Novartis: New Data Shows Efficacy Of Piqray In HR+/HER2- Metastatic Breast Cancer

BASEL (dpa-AFX) - Novartis (NVS) said new Piqray data showed benefit across a broad range of patient and disease characteristics in analyses from all three cohorts of BYLieve, an ongoing phase

Related Keywords

, Novartis , Data , Shows , Efficacy , Piqray , Ther2 , Metastatic , Breast , Dancer ,